Recently, relations between hypertension and infections caused by several pathogens have been reported. However, few studies have examined the relationship between human metapneumovirus (hMPV) and hypertension in elderly inpatients. To assess the association between anti-hMPV-immunoglobulin G (IgG) titer and the prevalence of hypertension, we conducted a case-control study in a Japanese long-term care facility (LTCF). The participants included 84 hypertensive patients aged X65 years, and 84 age-and sex-matched normotensive controls (38 males and 46 females in each group; cases, 79.9 ± 8.4 (s.d.) years; controls, 80.1 ± 8.3 years). Data on underling chronic clinical conditions were collected. Titers were measured using an immunofluorescence assay kit. The significance of risk factor differences was analyzed using univariate and multivariate comparisons of cases and controls. All serum samples were positive for hMPV, and IgG titers ranged from 40-fold to more than 5120-fold. There were no significant sex-or age-related differences in log 2 (anti-hMPV-IgG titer/10) among the subjects. Compared with normotensive subjects, hypertensive patients presented significantly higher log 2 (anti-hMPV-IgG titer/10) values (Po0.001). After adjustment with multiple logistic analysis, the odds ratio for log 2 (anti-hMPV-IgG titer/10) was 1.42 (95% confidence interval 1.16-1.75, P¼0.001) relative to normotensive subjects. In all subjects, stepwise multiple regression analysis revealed that both hypertension and a poor nutritional state independently contributed to increased log 2 (anti-hMPV-IgG titer/10). These observations suggest that an increased anti-hMPV-IgG titer was closely related to hypertension in elderly subjects in a Japanese LTCF.
INTRODUCTION
Human metapneumovirus (hMPV) was first isolated in children with acute respiratory tract illnesses in 2001. 1 This virus is a member of the genus metapneumovirus of the subfamily Pneumovirinae of the family Paramyxoviridae. hMPV induces infections of the lower respiratory tract, including bronchitis, bronchiolitis and pneumonia, in young children 2 and immunocompromised individuals, 3 along with upper respiratory tract illnesses and influenza-like illness. 4 In January 2005, we reported an outbreak of nosocomial hMPV infection in elderly subjects in a long-term care facility (LTCF) in Japan. 5 Several subsequent reports revealed that hMPV infection outbreaks frequently occur in LTCFs, 6 not only in the winter 5, 6 but also in summer, 7 with high mortality. Serological responses to hMPV-induced respiratory tract illnesses were frequently found (12.8%) among common viruses during a 52-week intervention period in residents of an LTCF. 8 Unlike other viral infections, which evoke lifelong immunity, hMPV reinfection occurs frequently, despite high rates of perpetual seroprevalence for all age groups. This finding suggests that reinfection occurs because humoral immune responses have a minor role in the clearance of hMPV. 9 However, the relationship between hMPV infection and the underlying chronic clinical conditions has not been adequately evaluated in elderly subjects. Therefore, the aim of this study was to determine the relationship between the titer of immunoglobulin (Ig) G antibody against hMPV (anti-hMPV-IgG titer) and clinical conditions, including hypertension, in elderly patients in a Japanese LTCF.
METHODS

Identification of cases and controls
Our study was conducted in a 640-bed ward of the Department of Internal Medicine of Hanwa-Senboku Hospital, a Japanese LTCF for the elderly. The research protocol was approved by the ethics committee of the hospital. We identified all elderly subjects aged X65 years with hypertension, which was defined as blood pressure of 4140/90 mm Hg or antihypertensive medication use. The controls were a random sample of normotensive subjects aged X65 years admitted to the same ward. The computerized admission lists served as the sampling frame, and we frequency matched the controls to the cases by sex and age ( ± 2 years) at a ratio of 1:1. The controls met the same eligibility criteria as the cases, but they did not have hypertension. All subjects who gave informed consent were enrolled in our study, and the blood samples were obtained between October and November 2007. Subjects were excluded if they (1) had a clinical diagnosis of secondary hypertension due to other diseases at the beginning of the study, (2) had serum creatinine levels X177 mmol l À1 (2.0 mg dl À1 ), (3) were in the critical phase of another acute illness (myocardial infarction, stroke, exacerbation of heart failure, pneumonia or renal failure), (4) received artificial feeding or (5) were immunocompromised because of systemic steroid use, metastatic cancer or cancer therapy.
Measurement of IgG titer against hMPV
IgG titer was measured using an indirect immunofluorescence assay kit from Mitsubishi Kagaku Bio-Clinical Laboratories (Tokyo, Japan), as described previously. 10 Serum that reacted with F protein at a dilution of X1:10 was defined as positive for anti-hMPV antibodies. IgG titers were calculated according to log 2 (anti-hMPV-IgG titer/10) for each serum sample, and the positive results at dilutions of 1:10 to 1:5120 were rated on a scale from 0 to 9.
Underlying chronic conditions
In Table 1 , we noted the presence of the following clinical features in the enrolled patients: stroke, ischemic heart disease, chronic congestive heart failure, chronic kidney disease, 11,12 dementia, 13 diabetes mellitus, dyslipidemia, 14 a bedridden state, obesity, 14 a poor nutritional state and lung disease. The personal physicians of the patients were involved in the diagnosis of these complications, which were further assessed by a committee consisting of the authors (except MO). Objective and routinely collected medical information was used to enhance the accuracy of the diagnoses. Only chronic conditions were recorded for the cases and their respective control subjects. A computerized pharmacy database was used to assess the drug use. Each pharmacy record included the drug type and dose, date and administration duration. Data collection for the controls commenced after they had been hospitalized the same number of weeks as their corresponding cases. The data were retrieved from medical records (by MO). Of the 84 elderly subjects with hypertension, 21 took angiotensin II-receptor blockers alone, 16 took angiotensin I-converting enzyme inhibitors alone, 18 took dihydropyridine calcium-channel blockers alone and 10 took two or more (out of three) classes of antihypertensives, plus diuretics. In all, 19 subjects with hypertension were not prescribed any antihypertensive agent.
Statistical analysis
Data are expressed as mean and s.d. for continuous variables. Between-group comparisons were conducted with a Mann-Whitney U-test or w 2 -test (Fisher's exact test when needed). Independently participating factors for hypertension were identified by multiple logistic regression analysis after adjustment for confounding variables. Common pitfalls associated with multivariate regression were avoided using the method described by Concato et al. 15 The odds ratio (OR) for hypertension associated with various conditions was calculated using logistic regression analysis, adjusting for age, sex, and all associated variables selected according to their univariate analysis P-value (Po0.20). 16 Estimates for OR and the corresponding two-sided 95% confidence intervals (CIs) that demonstrated statistical significance were derived from the regression model. Conditional logistic regression was used to control for potential confounding variables. Independent associations with log 2 (anti-hMPV IgG titer/10) titer values were assessed by stepwise multiple regression analysis, using age, sex and factors with P-values o0.2 in the univariate analysis. P-values o0.05 were considered significant. The data were analyzed using SPSS (v. 16.0, Chicago, IL, USA). Table 2 summarizes the clinical background and underlying chronic conditions in the control and hypertension groups. There were no significant differences between the two groups in age, sex, admission period or prevalence of diabetes mellitus, dyslipidemia, or underlying chronic conditions, except that the hypertension group tended toward a higher prevalence of a past history of stroke and chronic kidney disease than the control group.
RESULTS
Confirmation of clinical factors
Anti-hMPV-IgG titer in normotensive and hypertensive elderly inpatients All serum samples were positive for anti-hMPV-IgG. The titer ranged from 40Â to more than 5120Â in the 168 elderly inpatients, and the mean±s.d. value of log 2 (anti-hMPV-IgG titer/10) was 6.19±1.65. The mean±s.d. value of log 2 (anti-hMPV-IgG titer/10) in the hypertension group (6.63 ± 1.52) was significantly higher than in the control group (5.75 ± 1.67; P¼0.001; Figure 1 ). There was no significant difference in the mean±s.d. log 2 (anti-hMPV-IgG titer/10) values between any two subgroups with antihypertensive treatment in the hypertensive elderly subjects: 6.69 ± 1.49 in the angiotensin II-receptor blocker group (n¼21, P¼0.038); 6.57±1.66 in the angiotensin Iconverting enzyme inhibitor group (n¼16, P¼0.041); 6.50 ± 1.46 in the calcium-channel blocker group (n¼18); 6.30 ± 1.64 in multiantihypertensive group (n¼10); and 6.95±1.47 in the non-treatment hMPV and hypertension in elderly inpatients L Zeng et al group (n¼19). The mean values of log 2 (anti-hMPV-IgG titer/10) in the angiotensin II-receptor blocker (P¼0.075), angiotensin I-converting enzyme inhibitor (P¼0.339) and non-treatment groups were significantly higher (P¼0.005) than in the normotensive elderly subjects.
Multiple logistic regression analysis for independent association with hypertension Multivariate associations between hypertension risk and selected characteristics after adjustment for potential confounders are shown in Table 3 . Age, sex, log 2 (anti-hMPV-IgG titer/10) value, chronic kidney disease and stroke history were used as potential confounders. The log 2 (anti-hMPV-IgG titer/10) value was significantly related to an increased hypertension risk after adjustment for age, sex and potential confounding factors, with a matched OR estimate for hypertension of 1.42 (95% CI, 1.16-1.75, P¼0.001; Table 3 ). Conditional logistic regression analysis using the same confounding factors revealed that log 2 (anti-hMPV-IgG titer/10) was significantly related to an increased hypertension risk, both in the hypertension subjects treated with any of the antihypertensive agents (n¼65, OR: 1.34, 95% CI: 1.07-1.67, P¼0.011) and in untreated hypertensive subjects (n¼19, OR: 1.60, 95% CI: 1.10-2.31, P¼0.013).
Relationship between log 2 (anti-hMPV-IgG titer/10) and chronic clinical conditions Table 4 compares log 2 (anti-hMPV-IgG titer/10) values between the groups with and without chronic clinical conditions, including older age (480 years), male sex, obesity (body mass index X25 kg m À2 ), diabetes mellitus, dyslipidemia, stroke, ischemic heart disease, chronic congestive heart failure, chronic kidney disease, dementia, a bedridden state, a poor nutritional state represented by hypoalbuminemia, and lung disease. The log 2 (anti-hMPV-IgG titer/10) value was significantly (P¼0.020) higher in the 24 subjects with a poor nutritional state than in the 144 subjects with good nutrition. The log 2 hMPV and hypertension in elderly inpatients L Zeng et al (anti-hMPV-IgG titer/10) value tended to be higher (P¼0.190) in obese subjects (body mass index X25 kg m À2 ) than in non-obese subjects. There was no significant difference between the groups with and without other clinical conditions (Table 4 ). To determine the associating factors for log 2 (anti-hMPV-IgG titer/10) in all elderly subjects, a multiple stepwise regression analysis was carried out using age, sex, hypertension, a poor nutritional state and obesity as confounding factors. The analysis revealed that a poor nutritional state and hypertension were independent contributing factors for increases in log 2 (anti-hMPV-IgG titer/10) values in all subjects (Table 5) .
DISCUSSION
The present case-control study revealed that anti-hMPV-IgG titer was independently associated with hypertension after adjusting for confounding factors in elderly subjects in an LTCF. Moreover, the multiple stepwise regression analysis revealed that hypertension and a poor nutritional state, among many underlying clinical conditions, contributed to increases in serum anti-hMPV-IgG titer in all elderly subjects. Although subjects with a poor nutritional state, reflected by hypoalbuminemia, are known to be susceptible to viral infection, 17 the findings in this study that this condition was also a risk factor for hMPV infection in elderly subjects in LTCFs is novel. The precise mechanism(s) underlying the role of hypertension in anti-hMPV-IgG titer increases is unclear. One possible explanation is that some antihypertensive agents influenced the hMPV infection. In this study, however, there were no significant anti-hMPV IgG titer differences between any two subgroups of antihypertensive treatment, including the non-treatment subgroup in hypertensive elderly subjects; furthermore, the mean log 2 (anti-hMPV-IgG titer/10) values in the angiotensin II-receptor blocker, angiotensin I-converting enzyme inhibitor and non-treatment subgroups were significantly higher than in the normotensive elderly subjects. These observations suggest that antihypertensive agents have a minimal role in the increased anti-hMPV-IgG titers observed in the hypertensive elderly group.
The second possibility is that hypertension itself may cause higher anti-hMPV-IgG titers in the elderly. It is reported that patients with hypertension have significantly higher serum IgG levels in comparison with normotensive controls, 18 and that serum IgG levels were increased in patients who survived malignant phase hypertension. 19 Meanwhile, there have been several reports regarding the seroprevalence of hMPV infection around the world. Almost all people acquire seropositivity for hMPV by the age of 10 years, 2 and hMPV is known to infect individuals repeatedly throughout adult life and into old age. [5] [6] [7] [8] [9] Although there are no reports of IgG titer differences between patients with hypertension and normotensive controls after individual infections with pathogens, including hMPV, it is possible that hypertension itself may increase the anti-IgG titer in response to repeated hMPV infections in the elderly. In this present cross-sectional study, however, we could not show any time-course data for anti-hMPV-IgG titers in individual subjects.
The third possibility is that hypertension is the result of repeated hMPV infection. Several reports have associated the appearance of hypertension with predisposing repeated and/or chronic infections with many other pathogens, including Chlamydia pneumoniae, 20 herpes simplex virus type 2, 21 cytomegalovirus, 22 Coxsackie virus, 23 and Helicobacter pylori. 24 All these pathogens are known to directly affect vascular smooth muscle cells and/or vascular endothelial cells and to possibly cause the progression of atherosclerosis. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] On the contrary, there is no evidence to date that hMPV has a direct effect on vascular smooth muscle cells or endothelial cells. hMPV is reported to affect airway epithelial cells and stimulate massive production of interleukin-8, 30, 31 and regulate upon activation normal T-cell expressed and secreted. 31 On the other hand, interleukin-8 is known to closely relate to the genesis of hypertension because it enhances membrane permeability to Ca 2+ and induces vasoconstriction in smooth muscle cells 32 and because an antihypertensive calcium channel blocker, azelnidipine, is reported to reduce circulating interleukin-8 levels. 33 Moreover, circulating interleukin-8 is known to predict the development of atherosclerosis in coronary arteries. 34 On the other hand, regulate upon activation normal T-cell expressed and secreted is known to be a peripheral monocyte-related inflammatory marker related to hypertension. 35 It is possible that repeated hMPV infections cause spillover of these cytokines from the respiratory tract into the circulation, laying the foundation for hypertension in the elderly. Consequently, the findings of this study suggest that serum anti-hMPV-IgG titers contribute to the risk factors for hypertension in the elderly in LTCFs. Nevertheless, the specific underlying pathophysiological mechanisms that link hMPV with hypertension in the elderly have not yet been defined. Therefore, the precise mechanisms underlying the association between hMPV infection and hypertension should be determined in future basic and clinical studies. Table 5 Stepwise multiple regression analysis to assess independent determinants for log 2 (anti-hMPV-IgG titer/10) hMPV and hypertension in elderly inpatients L Zeng et al
